Merck Sharp + Dohme Corp.

Aaron Zwicker

Paul E Finke

Jianming Bao

F Anthony Romero

Feroze Ujjainwalla

Harold B Wood

Rajan Anand

Weiguo Liu

Petr Vachal

Joseph Leslie Duffy

Fengqi Zhang

Vincent Colandrea

Feng Ye

Debra L Ondeyka

Sriram Tyagarajan

Edward C Sherer

Yi Zang

Kake Zhao

Jonathan E Wilson

Remond Moningka

Zahid Hussain

Revathi Reddy Katipally

Michael A Plotkin

Patrick Shao

Maud Reiter

Joseph L Duffy

Vincent J Colandrea

Zahid Hussian

Anthony Romero

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

Substituted benzopiperazines as CETP inhibitors

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 

Spiroxazolidinone compounds

Growing community of inventors

New Haven, CT, United States of America

Aaron Zwicker